RXR can increase scavenging cells to clear dead cells and debris after a stroke in the brain, thus limiting inflammation and improving recovery, according to a study published in the journal Stroke. The discovery of RXR as a cleanup booster suggests that the molecule activating RXR could lead to discovery of a promising new therapeutic target.
‘The discovery of RXR as a cleanup booster suggests that the molecule activating RXR could lead to discovery of a promising new therapeutic target, which benefits stroke patients.’
Read More..Tweet it Now
"RXR could enhance the cleanup and reduce the injury to brain tissue caused by the toxic byproducts created by an ischemic stroke," said Aronowski, professor in the Department of Neurology at McGovern Medical School at UTHealth. "This could be a clinically relevant target for improving recovery."Read More..
After a stroke, there is a buildup of dead cells and debris in the brain, a toxic environment that leads to damaging inflammation. Phagocytic immune cells, such as microglia and blood-derived macrophages, occur naturally in the body and act as toxic cleanup warriors.
RXR appears to work by increasing potency of these warriors in combating the damaging effect of dead tissue while helping to boost brain repair.
In the trial, mice with an RXR gene selectively deleted in these immune cells had worsened late neurological recovery and developed larger brain atrophy compared to control mice.
But mice who received bexarotene, a retinoid medication that activates RXR, showed improved neurological recovery and had reduced atrophy volume.
Advertisement